FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)

Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Hamadi, Lee, Jeon‐Soo, Choi, Young Eun, Li, Yan, Kim, Myoung Hee, Choi, Yongdoo, Goh, Sung‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Cover Picture
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561766/
http://dx.doi.org/10.1002/advs.202270183
Descripción
Sumario:Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outcomes in immune‐resistant lung tumors. More details can be found in article number 2202702 by Yongdoo Choi, Sung‐Ho Go, and co‐workers. [Image: see text]

Ejemplares similares